Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study

David M Kern, Jill Davis, Setareh A Williams, Ozgur Tunceli, Bingcao Wu, Sally Hollis, Charlie Strange, Frank Trudo, David M Kern, Jill Davis, Setareh A Williams, Ozgur Tunceli, Bingcao Wu, Sally Hollis, Charlie Strange, Frank Trudo

Abstract

Background: Inhaled corticosteroid/long-acting β2-agonist combinations (ICS/LABA) have emerged as first line therapies for chronic obstructive pulmonary disease (COPD) patients with exacerbation history. No randomized clinical trial has compared exacerbation rates among COPD patients receiving budesonide/formoterol combination (BFC) and fluticasone/salmeterol combination (FSC) to date, and only limited comparative data are available. This study compared the real-world effectiveness of approved BFC and FSC treatments among matched cohorts of COPD patients in a large US managed care setting.

Methods: COPD patients (≥40 years) naive to ICS/LABA who initiated BFC or FSC treatments between 03/01/2009-03/31/2012 were identified in a geographically diverse US managed care database and followed for 12 months; index date was defined as first prescription fill date. Patients with a cancer diagnosis or chronic (≥180 days) oral corticosteroid (OCS) use within 12 months prior to index were excluded. Patients were matched 1-to-1 on demographic and pre-initiation clinical characteristics using propensity scores from a random forest model. The primary efficacy outcome was COPD exacerbation rate, and secondary efficacy outcomes included exacerbation rates by event type and healthcare resource utilization. Pneumonia objectives included rates of any diagnosis of pneumonia and pneumonia-related healthcare resource utilization.

Results: Matching of the identified 3,788 BFC and 6,439 FSC patients resulted in 3,697 patients in each group. Matched patients were well balanced on age (mean=64 years), gender (BFC: 52% female; FSC: 54%), prior COPD-related medication use, healthcare utilization, and comorbid conditions. During follow-up, no significant difference was seen between BFC and FSC patients for number of COPD-related exacerbations overall (rate ratio [RR]=1.02, 95% CI=[0.96,1.09], p=0.56) or by event type: COPD-related hospitalizations (RR=0.96), COPD-related ED visits (RR=1.11), and COPD-related office/outpatient visits with OCS and/or antibiotic use (RR=1.01). The proportion of patients diagnosed with pneumonia during the post-index period was similar for patients in each group (BFC =17.3%, FSC =19.0%, odds ratio=0.92 [0.81,1.04], p=0.19), and no difference was detected for pneumonia-related healthcare utilization by place of service.

Conclusion: This study demonstrated no difference in COPD-related exacerbations or pneumonia events between BFC and FSC treatment groups for patients new to ICS/LABA treatment in a real-world setting.

Trial registration: ClinicalTrials.gov identifier NCT01921127 .

Figures

Figure 1
Figure 1
Patient selection.
Figure 2
Figure 2
Kaplan-Meier curves for time to first COPD exacerbation and pneumonia diagnosis.

References

    1. American Lung Association. COPD fact sheet. 2011. Available from: . Last accessed June 6, 2013.
    1. What is COPD? National Heart Lung and Blood Institute; U.S.Department of Health & Human Services, 2013. Available from: . Last accessed June 20, 2013.
    1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance–United States, 1971–2000. Respir Care. 2002;47(10):1184–99.
    1. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S–6. doi: 10.1378/chest.121.5_suppl.121S.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, 2014. Available from: . Last accessed December 17, 2014.
    1. AstraZeneca LP. SYMABICORT Prescribing Information. 2010.
    1. GlaxoSmithKline. Advair DISKUS Package Insert, 2014. Available from: Last accessed October 22, 2014.
    1. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3:CD010844.
    1. Mapel DW, Roberts MH. Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting beta-agonists: a review of comparative effectiveness research. Drugs. 2014;74(7):737–55. doi: 10.1007/s40265-014-0214-8.
    1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65. doi: 10.1164/rccm.201204-0596PP.
    1. Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769–76. doi: 10.3111/13696998.2011.622817.
    1. Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32(7):1320–8. doi: 10.1016/j.clinthera.2010.06.022.
    1. Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273(6):584–94. doi: 10.1111/joim.12067.
    1. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS) BMJ. 2013;346:f3306. doi: 10.1136/bmj.f3306.
    1. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
    1. Mapel D, Schum M, Yood M, Brown J, Miller D, Davis K. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J. 2010;19(2):109–17. doi: 10.4104/pcrj.2009.00072.
    1. Nau DP. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. 2014.
    1. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037–49. doi: 10.1002/sim.3150.
    1. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092–7. doi: 10.1093/aje/kwq224.
    1. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques; In SAS SUGI 26, 2001, Paper 214–226. Available from: (SUGI 26), 214–226.
    1. Lee B, Lessler J, Stuart E. Improving propensity score weighting using machine learning. Stat Med. 2010;29:337–46.
    1. Liaw A, Wiener M. Classification and regression by random forest. R News. 2002;2(3):18–22.
    1. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2014, 42(7)
    1. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–36. doi: 10.1136/thoraxjnl-2012-202872.
    1. Halpin DM, Gray J, Edwards SJ, Morais J, Singh D. Budesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract. 2011;65(7):764–74. doi: 10.1111/j.1742-1241.2011.02685.x.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner